Experimental Vaccine to Prevent Fentanyl Overdose Enters Human Trials

An experimental “anti-fentanyl” vaccine developed by ARMR Sciences, Inc. of New York and the University of Houston has entered Phase 1/2 human trials, according to a June 17 press release issued by the company. The vaccine candidate has spent years in development and vaccine developers say it represents a potential intervention in America’s ongoing overdose epidemic, which claims the lives of an estimated 48,000 Americans annually; more than 100 per day, according to ARMR Sciences.^{1 2}

Board-certified cardiologist and internist Abeer Berry, MD says the vaccine was developed by combining a fentanyl-like molecule with components derived from diphtheria and E. coli. “In return, the body activates the immune system, and when it does, it creates antibodies that are able to bind to fentanyl,” Dr. Berry explained. “There is no drug that has had an impact on the overdose crisis like fentanyl,” he said in an interview.²

The long-term immunological effects of combining a fentanyl-like molecule with a diphtheria toxin-derived carrier protein and E. coli components in humans have not yet been established. ARMR-100, the name of the vaccine candidate, has completed only the first three cohorts of a Phase 1/2 dose-escalation trial, and no peer-reviewed safety data have been published.¹

“The antibody response we observed at the lowest dose level tested has been robust, with anti-fentanyl IgG titers well above pre-vaccination baseline. These early immunogenicity data are encouraging as we advance to higher dose cohorts and, ultimately, to the human fentanyl challenge phase of the study,” said Seth Toback, MD, Chief Medical Officer of ARMR Sciences.¹

No Known Placebo Disclosed in Anti-Fentanyl Vaccine Candidate ARMR1-100

ARMR Sciences reports that no serious medical events have been observed among the 24 participants dosed to date. Reported adverse events, the company states, have been “minor, infrequent, and short-lived, consisting primarily of occasional headaches and consistent with the typical response to other inoculations.” The press release does not disclose what, if any, control or comparator was used in the trial.¹

The U.S. Government Accountability Office (GAO) estimates that roughly 48,000 Americans die each year from overdoses linked to synthetic opioids like fentanyl, making the drug the biggest driver of fatal overdoses nationwide and, according to the National Safety Council, the leading cause of preventable injury-related death nationwide. The U.S. Centers for Disease Control and Prevention (CDC) states that fentanyl is involved in three-quarters of all drug overdoses nationwide.^{3 4}

Separate Fentanyl Vaccine Effort Remains in Preclinical Mouse Studies

Also in development is a separate, parallel vaccine effort by Scripps Research which, according to a June 13, 2026 press release, aims to target a broader range of fentanyl variants. “Each year, fentanyl and related synthetic opioids are responsible for more deaths than car crashes and gun violence combined,” the press release states. “In high doses, these drugs disrupt normal brain function and can suppress the signals that control breathing, often leading to fatal overdoses.” Instead of treating an overdose after it happens (with Narcan, for example), the team at Scripps Research is developing what the institute calls “an experimental vaccine designed to stop fentanyl from reaching the brain in the first place.”⁵

Unlike the ARMR Sciences vaccine currently in Phase 1/2 human trials, the Scripps Research vaccine remains in preclinical mouse studies. Scripps researchers say its broader antibody response may offer protection against the full class of fentanyl designer drugs; not just fentanyl itself. Fentanyl designer drugs, or fentanyl analogs, refer to chemically modified versions of fentanyl created by illicit manufacturers to increase potency, evade drug screening, or circumvent drug scheduling laws.^{5 6}

Public Health Crisis or Highly Lucrative Secondary Market for Pharmaceutical Companies?

The fentanyl epidemic follows a documented history of other illicit drug epidemics, many of which pharmaceutical companies responded to by developing pharmaceutical countermeasures that have become highly profitable cornerstones of the multibillion-dollar addiction management industry and significant revenue drivers. In the case of the opioid crisis itself, which originated in the mid- to late-1990s and was not declared a nationwide public health emergency until 2017, the pharmaceutical product that became a public health crisis was manufactured and marketed by pharmaceutical companies.⁷

Beyond that, pharmaceutical companies developed methadone as a countermeasure to heroin addiction, and later buprenorphine, marketed as Suboxone. Critics warn that these countermeasures carry their own risks, such as creating dependence. In many cases, it is standard practice that no taper or cessation plan is offered to the patient, meaning a majority of patients prescribed the opioid agonist drugs will remain on them for life. Both methadone and buprenorphine carry serious risks, including fatal overdose, respiratory depression, dangerous withdrawal complications, and severe cardiovascular effects; risks not dissimilar to those associated with the illicit opioids that preceded their prescriptions for opioid agonist therapy.⁸

Opioid Crisis Spawned Multibillion-Dollar Treatment Market and Fentanyl Vaccine Could Expand It Further

The financial interests of pharmaceutical manufacturers in both the substances that produced the epidemics (as in the case of the opioid crisis) and the treatments developed in response (such as methadone and Suboxone) remain a subject of ongoing litigation, legislation, and public scrutiny. In January 2025, the Congressional Research Service reported a $7.4 billion settlement between Purdue Pharma and the Sackler family resolving allegations of their role in fueling the opioid epidemic. As part of the settlement terms, the Sackler family is permanently banned from manufacturing, selling, or marketing opioids in the United States.⁹

No independent market projections for a commercially available fentanyl vaccine have been published. According to Grand View Research, the global opioid use disorder treatment market, which includes methadone, buprenorphine, and naltrexone, was valued at $5.28 billion in 2024 and is projected to reach $10.24 billion by 2030.¹⁰

A prominent talking point by public health officials and doctors persuading patients to get vaccinated during the COVID-19 pandemic was that it would prevent hospitalization and death. Data published by the CDC estimate that, despite a large number of the population having received one or more COVID injections, COVID was associated with an estimated 290,000 to 450,000 hospitalizations and 34,000 to 53,000 deaths between July 2024 and June 2025. The Center for Infectious Disease Research and Policy at the University of Minnesota (CIDRAP) concluded that up to 56,000 people died from COVID or RSV in 2025. Neither the CDC estimates nor the CIDRAP report disaggregate mortality data by vaccination status.¹¹

Researchers say a publicly available fentanyl vaccine remains years away. ARMR Sciences says the next phase of testing is on track to begin in the fall of 2026. Whether the anti-fentanyl vaccine will prove more effective at preventing death than the COVID injections, in a population in which a large proportion had received one or more doses, is not yet known.^{1 2}

If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.